Entecavir: a review of its use in chronic hepatitis B.

Abstract:

:Entecavir (Baraclude) is a novel nucleoside analogue of 2'-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus (HBV). In large, randomised, double-blind, phase III clinical trials in patients with chronic HBV infection, oral entecavir 0.5 or 1.0mg once daily for up to 96 weeks was superior to lamivudine 100 mg/day in improving hepatic histology, normalising aminotransferase levels and suppressing viraemia to levels undetectable by polymerase chain reaction (PCR) assay in nucleoside-naive hepatitis B e antigen (HBeAg)-negative (precore or core promoter mutants) and/or HBeAg-positive patients, and in lamivudine-refractory (persistent viraemia during lamivudine therapy) HBeAg-positive patients. In addition, the tolerability profile of entecavir was generally similar to that of lamivudine. Thus, entecavir is a primary option in the treatment of chronic HBV infection in both nucleoside-naive and lamivudine-refractory patients.

journal_name

Drugs

journal_title

Drugs

authors

Robinson DM,Scott LJ,Plosker GL

doi

10.2165/00003495-200666120-00009

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

1605-22; discussion 1623-4

issue

12

eissn

0012-6667

issn

1179-1950

pii

66129

journal_volume

66

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Steroid-refractory severe ulcerative colitis: what are the available treatment options?

    abstract::Approximately 15% of patients with ulcerative colitis will experience a severe episode requiring hospitalization. Although intravenous corticosteroids are the current first-line therapy for these patients, about 30% of patients do not respond to corticosteroids and require either an alternative anti-inflammatory agent...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868090-00001

    authors: Moss AC,Peppercorn MA

    更新日期:2008-01-01 00:00:00

  • Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer.

    abstract::Approximately 70% of invasive breast cancers have some degree of dependence on the estrogen hormone for cell proliferation and growth. These tumors have estrogen and/or progesterone receptors (ER/PR+), generally referred to as hormone receptor positive (HR+) tumors, as indicated by the presence of positive staining an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01394-w

    authors: Nunnery SE,Mayer IA

    更新日期:2020-11-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Lung tissue penetration of temocillin.

    abstract::Eight patients about to have the whole or part of a lung resected were given a 2g bolus dose of temocillin. A series of serum samples and a piece of peripheral lung tissue were collected and assayed for temocillin concentration. 30 minutes after drug administration, the mean serum and tissue concentrations were 172 mg...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500295-00031

    authors: Cowan W,Baird A,Sleigh JD,Gray JM,Leiper JM,Lawson DH

    更新日期:1985-01-01 00:00:00

  • Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

    abstract::The rapid spread of human immunodeficiency virus (HIV) infections and the grim outcome of these infections have focused interest on the possibilities for medical intervention. The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198734030-00004

    authors: Sandström EG,Kaplan JC

    更新日期:1987-09-01 00:00:00

  • Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.

    abstract::In a double-blind, parallel-group randomised trial of 3 months' duration, the efficacy of cyclandelate 800 mg twice daily in migraine prophylaxis was compared with that of flunarizine 5mg daily in 40 patients. In comparison with placebo and baseline values, both drugs significantly relieved symptoms of migraine as ass...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700332-00019

    authors: Nappi G,Sandrini G,Savoini G,Cavallini A,de Rysky C,Micieli G

    更新日期:1987-01-01 00:00:00

  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis

    abstract:BACKGROUND:The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/00003495-200464002-00005

    authors: Sever PS,Dahlöf B,Poulter NR,Wedel H,Beevers G,Caulfield M,Collins R,Kjeldsen SE,Kristinsson A,McInnes GT,Mehlsen J,Nieminen M,O'Brien E,Ostergren J,ASCOT Investigators.

    更新日期:2004-01-01 00:00:00

  • Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

    abstract::Crizotinib (Xalkori(®)) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor receptor and c-ros oncogene 1. In the EU, crizotinib has been conditionally approved for the treatment of adults with previously treate...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0142-z

    authors: Frampton JE

    更新日期:2013-12-01 00:00:00

  • Optimum management of the discharging ear.

    abstract::Discharge from the ear can be the result of many disease processes. The ear may discharge blood, pus, cerebrospinal fluid (CSF) or wax. Keratosis obturans, stenosis of the external meatus and benign tumours of the external meatus all lead to wax build-up, which may cause recurrent attacks of otitis externa. Malignant ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243020-00008

    authors: Ruddy J,Bickerton RC

    更新日期:1992-02-01 00:00:00

  • Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.

    abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969070-00004

    authors: Baldwin CM,Plosker GL

    更新日期:2009-01-01 00:00:00

  • An evaluation of pharmacological strategies for the prevention and treatment of acute renal failure.

    abstract::Acute renal failure (ARF) occurs frequently in hospitalised patients, and is associated with significant morbidity and mortality. The most common and generalised forms of acute renal failure are pre-renal conditions and intra-renal acute tubular necrosis (ATN). Pre-renal ARF in its pure state should be entirely revers...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059010-00005

    authors: Dishart MK,Kellum JA

    更新日期:2000-01-01 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11317050-000000000-00000

    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

    abstract::Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empaglifl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0457-z

    authors: Kim ES,Deeks ED

    更新日期:2015-09-01 00:00:00

  • Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

    abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0489-4

    authors: Trendowski M

    更新日期:2015-11-01 00:00:00

  • Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

    abstract:UNLABELLED:Levonorgestrel 6-capsule subdermal implants (Norplant) are an effective form of reversible contraception. When implanted under the skin of the upper arm, they release drug into the circulation at a relatively constant rate over 5 years. Generally, the cumulative pregnancy rate at the end of 5 years' levonorg...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855060-00019

    authors: Coukell AJ,Balfour JA

    更新日期:1998-06-01 00:00:00

  • Pharmacotherapeutic management of locally advanced prostate cancer: current status.

    abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11591500-000000000-00000

    authors: Martin JM,Supiot S,Berthold DR

    更新日期:2011-05-28 00:00:00

  • Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

    abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01320-0

    authors: Somasundaram A,Socinski MA,Villaruz LC

    更新日期:2020-06-01 00:00:00

  • Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

    abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753050-00012

    authors: Bryson HM,Faulds D

    更新日期:1997-05-01 00:00:00

  • Antiplatelet drugs: clinical pharmacology and therapeutic use.

    abstract::Because platelets are so important in thrombus formation, drugs which inhibit platelet function (the 'antiplatelet drugs') have considerable potential as antithrombotic agents. Among the antiplatelet drugs, only aspirin, sulphinpyrazone, dipyridamole, hydroxychloroquine, and clofibrate have had wide clinical trial. Th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918060-00002

    authors: Gallus AS

    更新日期:1979-12-01 00:00:00

  • Parenteral aminoglycoside therapy. Selection, administration and monitoring.

    abstract::Aminoglycosides are potent water-soluble antibiotics, with peak concentration-dependent bactericidal activity against many pathogenic aerobic Gram-negative bacilli and Staphylococcus aureus. For systemic therapy, they must be given parenterally (intravenously or intramuscularly). In the body they remain largely extrac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447060-00004

    authors: Kumana CR,Yuen KY

    更新日期:1994-06-01 00:00:00

  • Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0666-0

    authors: Garnock-Jones KP

    更新日期:2017-01-01 00:00:00

  • Balanced analgesia: what is it and what are its advantages in postoperative pain?

    abstract::The concept of balanced analgesia was introduced to improve analgesic efficacy and reduce adverse effects. A large amount of clinical data has documented improved analgesia by combining different analgesics, but data on reducing adverse effects are inconclusive. Balanced analgesia should be used whenever possible, and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958050-00002

    authors: Kehlet H,Werner M,Perkins F

    更新日期:1999-11-01 00:00:00

  • Antacids and ulcer healing. A review of the evidence.

    abstract::There have been a number of controlled trials of antacids in the treatment of patients with peptic ulcer disease. As a general rule the size of studies has been small and there have been difficulties ensuring adequate binding, because of the formulation and taste of the antacids. Despite these difficulties, antacids a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-199142020-00003

    authors: Walt RP,Langman MJ

    更新日期:1991-08-01 00:00:00

  • Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.

    abstract::Eplerenone (Inspra) is a selective aldosterone blocker. Oral eplerenone is approved for use in patients with left ventricular (LV) systolic dysfunction and clinical evidence of heart failure following acute myocardial infarction (MI) in the US and in European countries (e.g. the UK and The Netherlands). The addition o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464230-00005

    authors: Keating GM,Plosker GL

    更新日期:2004-01-01 00:00:00

  • Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

    abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969060-00004

    authors: Patel M

    更新日期:2009-01-01 00:00:00

  • Use of oral rehydration therapy in acute watery diarrhoea. A practical guide.

    abstract::Various foods and fluids have been used in traditional treatments for diarrhoeal illnesses in infants and children for centuries. During the last 2 decades, however, with the advent of an improved scientific understanding of oral rehydration, effective treatment of dehydrating diarrhoea has been improved, expanded and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141040-00005

    authors: Sack DA

    更新日期:1991-04-01 00:00:00

  • Elbasvir/Grazoprevir: First Global Approval.

    abstract::A fixed-dose combination tablet of the hepatitis C virus (HCV) NS5A inhibitor elbasvir and the HCV NS3/4A protease inhibitor grazoprevir (elbasvir/grazoprevir; Zepatier™) is under development by Merck. Oral elbasvir/grazoprevir 50/100 mg once daily has been approved in the USA for the treatment of adults with chronic ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0558-3

    authors: Keating GM

    更新日期:2016-04-01 00:00:00

  • Tuberculosis vaccines: current progress.

    abstract::Tuberculosis continues to be a major cause of disease and death throughout the developing world. Chemotherapy is the current method of control but with the continuing emergence of drug resistance, coupled with the reticence of major drug companies to invest in drug discovery, the identification of new vaccines to comb...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200565170-00002

    authors: Orme IM

    更新日期:2005-01-01 00:00:00

  • Lanthanum carbonate.

    abstract::Lanthanum carbonate is a novel, non-aluminium, non-calcium phosphate binding agent that forms a water-insoluble compound, lanthanum phosphate, in the gut. Lanthanum carbonate (elemental lanthanum 375-3000 mg/day) reduced serum phosphorus levels compared with placebo in two randomised, double-blind, multicentre 4-week ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464090-00008

    authors: Swainston Harrison T,Scott LJ

    更新日期:2004-01-01 00:00:00